Plan Ahead(TM) Test Offers Most Accurate Measurement of Women's Ovarian
ATLANTA, Jan. 21 /PRNewswire/ -- Georgia Reproductive Specialists (GRS) today announced it will be the first IVF center in the southeast to offer the Repromedix Plan Ahead(TM) test, an innovative blood test that provides an assessment of a woman's egg supply by combining multiple factors, including the measurement of ovary-related hormones AMH, Inhibin B, and FSH. The window of opportunity for a woman to have children by natural conception is dependent upon an adequate supply of eggs, which inevitably declines as a woman ages and her "biological clock ticks." Plan Ahead enables a woman to compare her estimated egg supply with the normal range expected for women of the same age.
The Plan Ahead Report provides valuable directional information about which women planning to have children after their late twenties should seek further advice from fertility experts to help ensure that those women with faster biological clocks can have the families they were hoping for.
"GRS has always incorporated the latest assisted reproductive technologies (ART) into our treatment plans to give our patients the best chance possible of having a baby, said Mark Perloe, M.D., Medical Director of Georgia Reproductive Specialists. "We strive to provide our patients with the most advanced testing and treatment options, so it is most appropriate that GRS is the first IVF center in the Southeast to offer the Plan Ahead test."
As women age, their fertility naturally declines, with increasingly
fewer eggs available for fertilization. "With so many women delaying
pregnancy until their 30s and 40s, women urgently need an accurate
assessment of their egg supply," said Dr. Perloe. "And while we know that
on average ovarian reserve begins a more rapid decline after age 35, it
varies among women of the same age. The Plan Ahead test will provide women
Copyright©2008 PR Newswire.
All rights reserved